EP-9001A / Easton Biopharma - LARVOL DELTA

First-in-human assessment of safety and pharmacokinetics of EP9001A:an anti-nerve growth factor antibody for chronic pain treatment. (PubMed, Br J Pharmacol) - "The dose-dependent pharmacokinetics and long half-life suggest the possibility of longer dosing intervals. Future trials should optimise dosing and evaluate long-term safety, particularly with respect to adverse musculoskeletal events arising through inhibition of nerve growth factor."

First-in-human • Journal • P1 data • PK/PD data • Immunology • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology

a Safety and Tolerability Study of EP-9001A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Chengdu Easton Biopharmaceuticals Co,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

Phase I Trial of EP-9001A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Chengdu Easton Biopharmaceuticals Co,Ltd

New P1 trial